Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1326-1336

  Ma, Ling Di ^a   Zhou, Min ^a   Wen, Shi Hong ^a   Ni, Cheng ^a   Jiang, Li Jia ^a   Fan, Jing ^a   Xia, Lei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cell cycle; CML; gene silencing; RNA interference; STAT3

Indexed keywords

CELL PROTEIN; LENTIVIRUS VECTOR; SMALL INTERFERING RNA; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CELL STRUCTURE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LENTIVIRINAE; MOLECULAR THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; GENE SILENCING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 77954107667     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.483748     Document Type: Article

References (29)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
2. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-2954.
3. Heaney NB, Holyoake TL. Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 2007;25:66-75.
4. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007;44:S4-S14.
5. Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;21:1-8.
6. Li G, Sun T, Su Y, et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 2008; 89:9-17.
7. Orth C, Moriggl R, Tsareva SA, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005;7:545-555.
8. Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;11:3367-3377.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
10. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCRABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008;7:3169-3175.
11. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007;36:184-204.
12. Matta H, Hozayev B, Tomar R, Chugh P, Chaudhary PM. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2003;2:211-212.
13. Kasschau KD, Carrington JC. A counterdefensive strategy of plant viruses: suppression of posttranscriptional gene silencing. Cell 1998;95:461-470.
14. Sambrook J, Russell D. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. pp 1.105-1.125.
15. Ilaria RL, Van Etten. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271: 31704-31710.
16. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996;10:1724-1730.
17. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17:6508-6516.
18. Coppo P, Flamant S, Veronique DM, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134:171-179.
19. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002;30:262-271.
20. Gagarin D, Yang Z, Butler J, et al. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mol Cell Cardiol 2005;39:453-465.
21. Yang J, Chatte M, Susan MS, et al. Novel roles of unphosphorylated STAT3 in oncogenesesis and transcriptional regulation. Cancer Res 2005;65:939-947.
22. Ivanov V, Bhoumik , Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001;7:517-528.
23. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell 1ines. Cancer Res 2000;60:5972-5976.
24. Banerjee SK, Weston AP, Zoubine MN, et al. Expression of cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma: relationship to cell death, proliferation and transformation. Am J Pathol 2000;156:217-225.
25. Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003;3:23-31.
26. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303-309.
27. Gao LF, Xu DQ, Wen LJ, Zhang XY, Shao YT, Zhao XJ. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 2005;26:377-383.
28. Coppo P, Dusanter-Fourt I, Millot G, et al. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003;22:4102-4110.
29. Coppo P, Dusanter-Fourt I, Vainchenker W, Turhan AG. BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 2009;21:52-60.